Results 141 to 150 of about 288,284 (303)

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
wiley   +1 more source

Management of Helicobacter pylori infection

JGH Open, Volume 7, Issue 1, Page 3-15, January 2023., 2023
Antibiotic‐resistant H. pylori strains have been increasing in most regions. Recommended first‐line regimens for H. pylori eradication are classified according to clarithromycin resistance. For patients with multiple treatment failure, antimicrobial susceptibility testing (AST) should be performed. Abstract Helicobacter pylori infection exhibits a wide
Natsuda Aumpan, Varocha Mahachai, Ratha‐korn Vilaichone   +2 more
wiley   +1 more source

Congenital Hypoplastic Thrombocytopenia with Skeletal Deformities in Siblings [PDF]

, 1959
Sidney Shaw, R. A. M. Oliver
openalex   +1 more source

Emerging Concepts in Immune Thrombocytopenia

Frontiers in Immunology, 2018
Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts which presents with an increased bleeding risk. Several genetic risk factors (e.g., polymorphisms in immunity-related genes) predispose to ITP.
Maurice Swinkels, M. Rijkers, J. Voorberg, G. Vidarsson, F. Leebeek, A. G. Jansen   +5 more
semanticscholar   +1 more source

Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps.
Rebecca Preyra, Lujain Ez Eddin, Fatemeh Ahmadi, Atefeh Jafari, Flory T. Muanda   +4 more
wiley   +1 more source

Observations on the Thrombocytopenia Due to Hypersensitivity to Quinidine [PDF]

, 1954
Percy Barkham, Leandro M. Tocantins
openalex   +1 more source

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

New England Journal of Medicine, 2021
Kate-Lynn E. Muir, A. Kallam, S. Koepsell, Krishna Gundabolu   +3 more
semanticscholar   +1 more source

Profound Thrombocytopenia and Dyspnea 11 Days After Cardiac Surgery

American Journal of Hematology, EarlyView.
Sebastian Vuong, Menaka Pai, Sarah Patterson, Theodore E. Warkentin   +3 more
wiley   +1 more source

Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

BMEMat, EarlyView.
This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan, Ye Zhu, Zhi Ye, Huayang Zhang, Junxi Wang, Guozhong Yi, Zhiyong Li, Rongyang Xu, Luyao Wang, Zhenzhen Wu, Songtao Qi, Guanglong Huang, Shanqiang Qu   +12 more
wiley   +1 more source

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

Journal of Hepato-Biliary-Pancreatic Sciences, Volume 30, Issue 1, Page 102-110, January 2023., 2023
Ioka and colleagues present the results of a phase III study comparing gemcitabine and cisplatin plus S‐1 (GCS) with gemcitabine and cisplatin for unresectable or recurrent biliary tract cancer. GCS demonstrated survival benefits and a higher response rate, and could be the new standard chemotherapy for advanced biliary tract cancer.
Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue, Masahiro Takahashi, Masayuki Sho, Keiko Kamei, Jiro Fujimoto, Masanori Toyoda, Junzo Shimizu, Takuma Goto, Yoshitaro Shindo, Kenichi Yoshimura, Etsuro Hatano, Hiroaki Nagano, Kansai Hepatobiliary Oncology Group (KHBO)   +21 more
wiley   +1 more source